Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, February 1999, p. 233-239, Vol. 43, No. 2
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Amphotericin B and Fluconazole Affect Cellular Charge, Macrophage
Phagocytosis, and Cellular Morphology of Cryptococcus
neoformans at Subinhibitory Concentrations
Joshua D.
Nosanchuk,1
Wendy
Cleare,2
Sarah P.
Franzot,3 and
Arturo
Casadevall1,2,*
Department of
Medicine1 and
Department of Microbiology
and Immunology,2 Albert Einstein College of
Medicine, Bronx, NY 10461, and
Department of Pharmacology,
Cornell University, New York, New York 100213
Received 15 July 1998/Returned for modification 8 October
1998/Accepted 9 November 1998
 |
ABSTRACT |
Amphotericin B (AmB) and fluconazole (FLU) are the major antifungal
drugs used in the treatment of cryptococcosis. Both drugs are believed
to exert their antifungal effects through actions on cell membrane
sterols. In this study we investigated whether AmB and FLU had other,
more subtle effects on C. neoformans that could contribute
to their therapeutic efficacy. C. neoformans cells were
grown in media with subinhibitory concentrations of either AmB or FLU
and analyzed for cellular charge, phagocytosis by macrophages with
antibody and complement opsonins, appearance by scanning electron and
light microscopies, and release of the capsular polysaccharide
glucuronoxylomannan into the culture medium. Growth in the presence of
either AmB or FLU resulted in major reductions in cellular charge, as
measured by determination of the zeta potential. Phagocytosis studies
demonstrated that exposure of C. neoformans to
subinhibitory concentrations of AmB or FLU enhanced phagocytosis by
macrophages. Scanning electron microscopy revealed that a large
proportion of cells had an altered capsular appearance. Cells grown in
medium with either AmB or FLU were smaller and released more
glucuronoxylomannan into the culture medium than cells grown without
antibiotics. The results suggest additional mechanisms of action for
AmB and FLU that may be operative in body compartments where drug
levels do not achieve the MICs. Furthermore, the results suggest
mechanisms by which AmB and FLU can cooperate with humoral and cellular
immune defense systems in controlling C. neoformans infections.
 |
INTRODUCTION |
Cryptococcus neoformans
is an opportunistic fungal pathogen that causes life-threatening
meningoencephalitis in 5 to 10% of AIDS patients (11, 36,
61). Amphotericin B (AmB) and fluconazole (FLU) are the most
common antifungal agents used in the treatment of infections caused by
C. neoformans. Despite treatment, AIDS patients frequently
relapse (54, 61), and therefore, antifungal agents are used
for life-long prophylactic suppression (14). AmB is a
polyene antibiotic that is thought to mediate antifungal effects by
binding to cell membrane sterols and damaging the cell membrane
(2). AmB may also function as an immunomodulator because it
has been shown to promote nitric oxide release (38), reduce virulence (56), enhance superoxide production (57,
58), and affect cytokine secretion (59). However,
levels of AmB in the tissue and the cerebrospinal fluid of humans are
frequently below fungicidal levels (10, 18, 35). FLU
inhibits ergosterol synthesis and is usually fungistatic for C. neoformans (51). Nevertheless, administration of either
AmB or FLU can usually control cryptococcosis.
We postulated that AmB and FLU have other, nonclassical mechanisms for
their activity. The relationship between cellular charge and
phagocytosis in microbial pathogens is complex and poorly understood
(12, 43). C. neoformans cells are negatively
charged (47). Since antibiotic administration reduces
bacterial cell charges (13, 37), we hypothesized that
exposure of C. neoformans to AmB or FLU would decrease the
magnitude of the negative charge and thus lessen the electrostatic
repulsion between the yeast and phagocytic cells. Zeta potentials were
calculated for cryptococcal cells with and without exposure to
subinhibitory concentrations of AmB or FLU. Phagocytosis assays were
performed on these cells to evaluate whether these changes in cellular
charge resulted in differences in the ability of macrophages to engulf
the organisms. Morphological analysis of cells grown with and without
AmB or FLU was accomplished by light and scanning electron
microscopies. In addition, supernatants from cultures grown with or
without these drugs were tested for cryptococcal polysaccharide.
 |
MATERIALS AND METHODS |
C. neoformans strains.
C. neoformans
serotype D strains ATCC 24067 and ATCC 3501 were obtained from the
American Type Culture Collection (Rockville, Md.). CAP67 is an
acapsular mutant (3) obtained from E. Jacobson (Richmond,
Va.). Strain ATCC 24067 was selected for study because it is an
extremely well characterized isolate which is used by many
investigators (21). Strain ATCC 3501 is the parent of CAP67, and CAP67 can be restored to virulence and the encapsulated state by
complementation with a single gene (7). Serotype D isolates are pathogenic for humans and are common in Europe (17).
The MICs of AmB (Boehringer Mannheim Inc., Mannheim, Germany) and FLU
(Roerig-Pfizer, New York, N.Y.) were determined by the macrodilution
method proposed by the National Committee for Clinical Laboratory
Standards (45). RPMI 1640 medium (Sigma Chemical Co., St.
Louis, Mo.) supplemented with L-glutamine, without
bicarbonate, buffered to a pH of 7.0 with 0.165 M MOPS
(morpholinepropanesulfonic acid; Sigma) was used for the assays.
Polystyrene plastic tubes containing 0.1-ml aliquots of each drug at 10 times the final concentration were inoculated with approximately 2,500 cells/ml in 0.9 ml of RPMI 1640 medium. Final drug concentrations
ranged from 0.03 to 128 µg/ml for FLU and 0.03 to 2 µg/ml for AmB.
The cells were incubated at 35°C for 72 h, and the MICs were the
lowest concentration that achieved 80% growth inhibition compared to the growth of the drug-free control for FLU and the lowest
concentration at which there was absence of growth for AmB. The MICs of
FLU for ATCC 24067, ATCC 3501, and CAP67 were 1, 0.5, and 1 µg/ml, respectively. The MICs of AmB for the three strains were 0.25, 0.125, and 0.25 µg/ml, respectively.
Strains were grown in Sabouraud broth (SAB; Difco Laboratories,
Detroit, Mich.) or 10% fetal calf serum (FCS; Bioproducts
for Science,
Indianapolis, Ind.) alone and supplemented with AmB
or FLU. Cultures
with antifungal agents were grown in the presence
of drug at
concentrations that were either 0.0125, 0.25, or 0.5
the MIC for the
strain. The cultures were inoculated with 3 ×
10
3
cells/ml and were incubated at 30°C with shaking for 48
h.
Measurement of cellular charge.
The zeta potential (
) is
a measurement of cellular charge (in millivolts) that is defined as the
potential gradient that develops across the interface between a
boundary liquid in contact with a solid and the mobile diffuse layer in
the body of the liquid (50). It is derived from the equation
= (4
m)/D, where D is the dielectric
constant of the medium,
is the viscosity, and m is the
electrophoretic mobility of the particle (50).
Cells grown in SAB as described above were collected and washed three
times in 0.01 M sodium chloride (pH 7.0). The zeta potentials
of
suspensions of 10
6 cells/ml were measured with a Pen Kem
model 501 Lazer Zee meter
(
24). The Lazer Zee machine
determines the zeta potentials of
the suspended cells by analyzing 20 to 30 cells simultaneously.
This method provides an accurate
measurement of the mean cellular
charge for a suspension of cells
(
24) and has previously been
used to measure cellular charge
for
C. neoformans (
47).
Phagocytosis assays.
J774.16 is a well-characterized murine
macrophage-like cell line (6) that has been extensively used
to study C. neoformans-macrophage interactions. The J774.16
cells were maintained at
80°C prior to use and were prepared for
the phagocytosis assays as described previously (9).
C. neoformans cells were grown in SAB as described above
with or without 0.5 the MIC of either AmB or FLU, collected, and washed
three times in 10% heat-inactivated FCS. Cells were added to the
J774.16 monolayer in a macrophage-to-yeast ratio of 1:1. The plates
were incubated for 2 h at 37°C with either 20% FCS (not heat
inactivated) or 10 µg of the monoclonal antibody (MAb) 18B7 per ml.
MAb 18B7 binds to cryptococcal glucuronoxylomannan (GXM)
(4). The monolayer was washed three times with
phosphate-buffered saline (PBS; 0.137 M NaCl, 0.003 M sodium phosphate
[pH 7.4]) to remove nonadherent cells, fixed with cold methanol, and
stained with Giemsa (Sigma). The phagocytic index is the number of
internalized yeast cells per number of macrophages per field.
Internalized cells were differentiated from attached cells by their
presence in a well-defined phagocytic vacuole. These measurements were determined by light microscopy (Nicon Diaphot; Nikon, Inc., Instrument Division, Garden City, N.J.) at a magnification of ×600. For each experiment three wells were examined, and the numbers of ingested cryptococcal cells and macrophages in three fields were counted, with
approximately 200 macrophages per field.
Electron microscopy.
C. neoformans cells were grown in
SAB or 10% FCS with or without either AmB or FLU at a concentration of
0.5 the MIC. Additionally, strains ATCC 3501 and CAP67 were grown in
10% FCS at concentrations of 0.125 and 0.25 the MIC of AmB. The cells
were collected, washed three times with PBS, and then incubated in
2.5% glutaraldehyde for 1 h at room temperature. The samples were
then applied to a polylysine-coated coverslip and serially dehydrated
in alcohol. The samples were fixed in a critical-point drier
(Samdri-790; Tousimis, Rockville, Md.), coated with gold-palladium
(Desk-1; Denton Vacuum, Inc., Cherry Hill, N.J.), and viewed with a
JEOL (Tokyo, Japan) JSM-6400 scanning electron microscope. Two separate sets of cultures were prepared. Cells from strains ATCC 3501 and ATCC
24067 were considered abnormal if the capsule was significantly distorted or absent. CAP67 is typically lemon shaped, and round cells
were considered abnormal.
Cell and capsule measurements.
In addition to evaluation by
electron microscopy, strains ATCC 3501 and ATCC 24067 that had been
grown in SAB were also evaluated by light microscopy. India ink
preparations were made and viewed with an Olympus AX70 (Melville, N.Y.)
microscope under oil immersion at a magnification of ×1,000 with a
grid with resolutions to 0.1 µm. The measurements for the capsule and
the organism were averaged (n = 20). Capsule thickness
was defined as the distance from the cell wall to the outer capsular
border, and organism size was defined as the cell diameter inclusive of
the polysaccharide capsule.
Measurement of capsular polysaccharide.
Supernatants from
48-h cultures of strains ATCC 3501 and ATCC 24067 grown in SAB or 10%
FCS with and without 0.5 the MIC of AmB or FLU were analyzed by
enzyme-linked immunosorbent assay for GXM. GXM is the major component
of C. neoformans polysaccharide (8). The cell
density for each culture was determined with a hemacytometer. Samples
were spun to pellet the cells, and a 1/50 dilution of supernatant was
made in Tris-buffered saline (25 mM Tris, 126 mM NaCl, 2.6 mM KCl [pH
7.2]). GXM levels in the sample supernatants were determined by
capture enzyme-linked immunosorbent assay relative to the levels in the
supernatant of the strain ATCC 24067 GXM standard (5). The
GXM determinations were normalized by dividing the GXM concentrations
by cell density.
Statistics.
Data were analyzed by using analysis of
variance, independent Student's t test, and chi-square test
with Primer for Statistics, version 3.0 (McGraw-Hill, Inc., New York,
N.Y.). All data are expressed as averages ± standard deviations.
 |
RESULTS |
Cellular charge.
The measured potentials for ATCC 24067, ATCC
3501, and CAP67 cells grown with and without subinhibitory
concentrations of AmB or FLU are listed in Table
1. The cellular charges for these strains
in the absence of drug were similar to previous determinations (47). Growth of these strains in the presence of AmB or FLU resulted in cells with significantly reduced cellular charges. AmB had
a more pronounced effect than FLU in reducing cellular charge for
strains ATCC 3501 and CAP67. For strain ATCC 24067, the drugs acted
similarly at 0.5 the MIC, but FLU at 0.25 the MIC had a greater effect
than 0.25 the MIC of AmB. Hence, for all strains, growth in the
presence of sub-MICs of AmB and FLU reduced the magnitude of the
negative cell charge.
Phagocytosis.
Significantly more cryptococcal cells grown in
the presence of the sub-MIC of either AmB or FLU were phagocytosed
compared with the numbers of phagocytosed cells grown in the absence of antifungal drugs (Fig. 1). In the
presence of MAb 18B7, AmB significantly enhanced the phagocytosis of
ATCC 3501 and ATCC 24067 compared to the level of phagocytosis of cells
grown with FLU. However, phagocytosis of cells grown with either
antifungal drug were engulfed by macrophages more frequently than
control cells. With complement-derived opsonins, there was no
significant difference in the level of phagocytosis of cells grown in
FLU compared to the level of phagocytosis of cells grown in AmB, but
more cells grown in the presence of antifungal drug than control cells
were phagocytosed. Thus, for all strains, cells grown in the presence
of the sub-MIC of AmB or FLU were more likely than control cells to be
phagocytosed with either antibody or complement opsonins.

View larger version (44K):
[in this window]
[in a new window]
|
FIG. 1.
Phagocytic index (number of organisms engulfed divided
by number of macrophages) for strains of C. neoformans grown
with or without antifungal agents. MAb, MAb 18B7; comp, complement from
20% FCS (not heat inactivated). Each bar represents the results for
three wells. *, P 0.001 for comparison of the
results for either AmB- or FLU-treated cells with those for the PBS
control for each group of experiments.
|
|
Scanning electron microscopy.
Scanning electron microscopy was
used to analyze the shapes of the cells and the state of the
polysaccharide capsule. Abnormal cells were seen in all samples of each
strain, but atypical forms were significantly more common in cultures
grown in SAB or 10% FCS with either FLU or AmB (Table
2). Atypical cells of encapsulated strains ATCC 24067 and ATCC 3501 consisted of organisms that were shedding or that had lost their capsules. Whereas CAP67 cells usually
appear lemon shaped, atypical cells were round. Figure 2 shows representative normal and
abnormal cells. For strain ATCC 3501, growth in SAB with AmB resulted
in more abnormal cells than growth in SAB with FLU (P = 0.025). For strains ATCC 24067 and CAP67 there were no significant
differences in the number of abnormal cells found after growth in
either SAB or 10% FCS with AmB or FLU. A greater incidence of abnormal
cells was seen with or without antifungal agents in the cultures grown
in 10% FCS. Decreasing the concentration of AmB to 0.125 and 0.25 the
MIC resulted in fewer abnormal cells (Table
3).

View larger version (48K):
[in this window]
[in a new window]
|
FIG. 2.
C. neoformans cells grown in the presence of
subinhibitory concentrations of AmB or FLU vary morphologically.
Encapsulated cryptococcal cells of strain ATCC 24076 grown in medium
with 0.5 the MIC of AmB can appear normal (A) or have shed part or all
of their capsules (B and C, respectively). Acapsular strain CAP67
typically appears in the shape of a lemon (D) but more commonly appears
round when it is grown with 0.5 the MIC of AmB or FLU (E).
Magnifications, ×2,000.
|
|
View this table:
[in this window]
[in a new window]
|
TABLE 3.
Effect of different subinhibitory concentrations of AmB
on cell morphology as detected by scanning electron microscopy
|
|
Cell and capsule measurements.
Measurements of the
encapsulated strains ATCC 24067 and ATCC 3501 grown with and without
0.5 the MIC of AmB or FLU were performed. For both strains, cells were
larger in size, with bigger capsules when they were grown without
antibiotics relative to the capsule size when they were grown with
either drug (Table 4). Since the capsule
has been shown to be the primary factor in determining the large
negative cellular charge of C. neoformans (47),
the measurements were normalized for capsule size and total
organism size, and the normalized values were significantly
different between cells grown without antibiotics and those grown with
AmB or FLU. Capsule size was reduced to a greater extent by AmB
than by FLU; however, there was no significant difference for the
normalized values.
GXM shedding.
The concentration of soluble polysaccharide in
the form of GXM was measured in the culture supernatants of cells grown
in SAB with or without 0.5 the MIC of AmB or FLU. Supernatants from cultures grown with either drug contained higher concentrations of GXM
than supernatants from cultures grown without antibiotics (Table
5). AmB had the greatest effect on
capsular release. Similar results were obtained when cells were grown
in 10% FCS, and the magnitude of the effect diminished with decreasing
concentrations of either antifungal agent from 0.5 to 0.25 and 0.125 the MIC (data not shown).
 |
DISCUSSION |
The major antifungal effects of AmB and FLU are considered to be
mediated via binding of cell membrane sterols and alteration of sterol
formation, respectively. However, there is also considerable evidence
that AmB can function as an immunomodulator (28, 38, 56-59). In this study, we demonstrated that growth of C. neoformans in the presence of subinhibitory levels of either AmB
or FLU had a wide range of effects on the organism, including (i)
reduced negative cell charge, (ii) decreased antiphagocytic properties, (iii) altered cell morphology with a reduction in cell and capsule size, and (iv) increased levels of release of capsular GXM into culture supernatants.
Antibiotic administration has been shown to significantly and rapidly
alter bacterial cell surface charges (13, 37), and these
changes can enhance bacterial uptake by phagocytes (42, 49).
Subinhibitory concentrations of macrolides have been shown to diminish
the production of extracellular polysaccharide in Staphylococcus
aureus (48). In C. neoformans, the reduction of cell charge and the more avid phagocytosis of cells grown in the
presence of sub-MICs of AmB and FLU are probably related, at least in
part, to the observation that these cells have smaller polysaccharide
capsules. The C. neoformans capsule is antiphagocytic (31) and confers a large negative charge on the cell
(33, 47). An inverse association between capsule size and
cell phagocytosis has been documented for several cryptococcal strains
(1, 19, 26, 53, 60). Furthermore, poorly encapsulated and
acapsular cells are rapidly phagocytosed and are nonpathogenic (3,
7, 22, 34). The increased concentration of GXM in the
supernatants of cells grown with subinhibitory concentrations of AmB or
FLU suggests that the drugs promote capsule shedding. Thus, the
diminution in cell and capsule sizes observed for cells grown with AmB
or FLU correlates with the alteration in cell charge measured for strains ATCC 24067 and ATCC 3501. However, despite the lack of a
polysaccharide capsule, strain CAP67 was also noted to have a profound
change in cellular charge after growth in the presence of these drugs.
This indicates that additional alterations in other cellular structures
are occurring, resulting in a net reduction in cellular charge.
Although the antiphagocytic properties of the C. neoformans
capsule are probably related to its high negative charge, the relationship between cell charge and phagocytosis is not well understood for microorganisms. Studies with polysytene and polyacrolein microspheres have demonstrated a dependence of macrophage phagocytosis on the charge, size, and hydrophobicity of the microspheres (27, 29, 55). However, phagocytosis of bioactive microspheres is also
highly dependent on the milieu in which the interaction occurs (25). In our study, both encapsulated and nonencapsulated
cryptococcal organisms grown in medium with sub-MICs of AmB or FLU were
more avidly phagocytosed by macrophages than were cells from the same strain grown in medium without drug. The effect was observed with both
complement-derived and antibody opsonins. Presumably, the decreased
magnitude of cell charge observed in the cells grown with antibiotic
facilitated increased interactions with macrophages. For Candida
albicans, growth of the yeast with antifungal drugs, including
AmB, has been shown to diminish the cellular charge and increase the
adherence of the cells to acrylic surfaces (37). Another
factor in the efficiency of phagocytosis is cell size. Large
cryptococcal cells are difficult for macrophages to ingest. Hence, the
reduction in cell size observed for cells grown with AmB or FLU may
have increased the level of ingestion independently of the effects of
cellular charge.
The observation that complement-derived and antibody opsonins were
significantly more effective in promoting phagocytosis of cells grown
in the presence of AmB or FLU suggests a mechanism by which these drugs
could cooperate with the immune system to promote containment of the
fungal infection. The combination of antibody and either drug has been
shown to be more effective than either agent alone in vivo and in vitro
(16, 40, 41). Our observations suggest that drug
administration may result in fungal cell changes that enhance the
efficacy of antibody in promoting the clearance of infection through
phagocytic cells. Human serum can inhibit multiplication of C. neoformans and can enhance the activity of FLU (44). In
addition, exposure of C. neoformans to human serum results
in the deposition of C3 fragments via activation of the alternative
pathway (30). The increased incidence of cells that appear
to be abnormal in the cultures grown in 10% FCS compared to their
incidence in the SAB cultures suggests that normal components of serum
can affect cell characteristics and may augment the effects of AmB and FLU.
We previously demonstrated that both antibody and AmB can enhance
nitrogen oxide production in macrophages (38, 39). Thus, the
effect of AmB on antibody-mediated phagocytosis may be additive or
synergistic. Furthermore, the observation that MAb 18B7 promoted phagocytosis, despite a reduction in capsule size, indicates that the
epitopes recognized by this antibody are expressed in cells exposed to
these drugs. This finding is important given that MAb 18B7 is planned
to be used as an adjunct to antifungal therapy in patients with
cryptococcosis (4).
The mechanisms by which growth in AmB or FLU alters cell and capsule
size and cell shape are unknown. Exposure of cells to subinhibitory
concentrations of AmB or FLU has been shown to alter their lipid
profiles (20, 23), and these changes may affect the shape of
the yeast cells. Regulation of cell shape is a complex process
influenced by factors such as osmotic pressure, temperature, and
nutrition. Specific genes have been shown to regulate cell shape in
some types of yeast (15, 52). Exposure of cryptococcal cells
to either AmB or FLU may constitute a stress that induces changes in
gene expression that consequently results in alteration in cell size.
The mechanism by which these drugs increased the level of
polysaccharide shedding is also not understood. Little is known about
the attachment of the polysaccharide capsule to the cell wall except
for the fact that it is reversible (32). Like the changes in
cell size, the increased release of GXM may reflect alterations in the
cell wall and/or changes in gene regulation as a consequence of cell stress.
Two previous studies in the literature are relevant to the findings
reported here. In 1974, Borowski et al. (1) reported that
growth of C. neoformans in the presence of low
concentrations of AmB could reduce the size of the capsule and
promote serum-mediated phagocytosis by murine macrophages. To our
knowledge, that report was never followed up by further studies. In
1991, Dromer and Charreire (16) did investigate the binding
of an anticapsular MAb to C. neoformans cells exposed
to AmB and showed that the average fluorescence intensity increased and
that AmB-treated cells were more avidly phagocytosed by murine
macrophages. Although the mechanism of action of this effect was not
investigated, the investigators suggested that AmB might alter the
capsular structure. Our observations are consistent with these prior
reports and also extend these findings to FLU. Furthermore, we
demonstrated that the differences in capsule size are accompanied by
changes in cellular charge, cell size, and the amount of polysaccharide
that is shed.
Our results suggest a potential explanation for the common clinical
observation that antifungal agents can be effective when their
concentrations in tissue are below the MIC for C. neoformans (10, 35, 46). Our results indicate that
exposure to a sub-MIC of AmB or FLU can alter C. neoformans cells in a manner that could reduce their virulence
and/or increase their susceptibility to host immune mechanisms. The
changes in C. neoformans resulting from exposure to
drug at levels below the MIC may represent additional mechanisms of
drug action that contribute to the effectiveness of these medications.
Studies of the effects of drugs at subinhibitory levels may be a
fertile area for investigation into the mechanism of drug action.
 |
ACKNOWLEDGMENTS |
This work was supported by grants from NIH (grants RO1-AI22774,
AI13342, and HL59842 [to A.C.] and grant K08-AI01489 [to
J.D.N.]) the Burroughs Wellcome Trust (to A.C.), a minority
student supplement to NIH grant RO1-AI33774 (to W.C.), and the
Infectious Diseases Society of America (to J.D.N.).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Medicine, Albert Einstein College of Medicine, 1300 Morris Park Ave., Bronx, NY 10461. Phone: (718) 430-3659. Fax: (718) 430-8968. E-mail: casadeva{at}aecom.yu.edu.
 |
REFERENCES |
| 1.
|
Borowski, J.,
P. Jakoniuk,
W. Jablonska,
W. Jakubicz, and A. Szpak.
1974.
The influence of antifungal antibiotics on some determinants of virulence in Candida albicans and Cryptococcus neoformans cells.
Experientia
30:1210-1211[Medline].
|
| 2.
|
Brajtburg, J.,
W. G. Powderly,
G. Kobayashi, and G. Medoff.
1990.
Amphotericin B: current understanding of mechanism of action.
Antimicrob. Agents Chemother.
34:183-188[Free Full Text].
|
| 3.
|
Bulmer, G. S.,
M. D. Sans, and C. M. Gunn.
1976.
Cryptococcus neoformans. I. Nonencapsulated mutants.
J. Bacteriol.
94:1475-1479.
|
| 4.
|
Casadevall, A.,
W. Cleare,
M. Feldmesser,
A. Glatman-Freedman,
D. L. Goldman,
T. R. Kozel,
N. Lendvai,
J. Mukhergee,
L.-A. Pirofski,
J. Rivera,
A. L. Rosas,
M. D. Scharff,
P. Valadon,
K. Westin, and Z. Zhong.
1998.
Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies.
Antimicrob. Agents Chemother.
42:1437-1446[Abstract/Free Full Text].
|
| 5.
|
Casadevall, A.,
J. Mukherjee, and M. D. Scharff.
1992.
Monoclonal antibody based ELISA for cryptococcal polysaccharide.
J. Immunol. Methods
154:27-35[Medline].
|
| 6.
|
Chan, J.,
Y. Xing,
R. S. Magliozzo, and B. R. Bloom.
1992.
Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages.
J. Exp. Med.
175:1111-1122[Abstract/Free Full Text].
|
| 7.
|
Chang, Y. C., and K. J. Kwon-Chung.
1994.
Complementation of a capsule-deficient mutation of Cryptococcus neoformans restores its virulence.
Mol. Cell. Biol.
14:4912-4919[Abstract/Free Full Text].
|
| 8.
|
Cherniak, M. R., and J. B. Sundstrom.
1994.
Polysaccharide antigens of the capsule of Cryptococcus neoformans.
Infect. Immun.
62:1507-1512[Abstract/Free Full Text].
|
| 9.
|
Cleare, W., and A. Casadevall.
1998.
The different binding patterns of two immunoglobulin M monoclonal antibodies to Cryptococcus neoformans serotype A and D strains correlate with serotype classification and differences in functional assays.
Clin. Diagn. Lab. Immunol.
5:125-129[Abstract/Free Full Text].
|
| 10.
|
Collette, N.,
P. Van der Auwera,
F. Meunier,
C. Lambert,
J. P. Sculier, and A. Coune.
1991.
Tissue distribution and bioactivity of amphotericin B administered in liposomes to cancer patients.
J. Antimicrob. Chemother.
27:535-548[Abstract/Free Full Text].
|
| 11.
|
Currie, B. P., and A. Casadevall.
1994.
Estimation of the prevalence of cryptococcal infection among HIV infected individuals in New York City.
Clin. Infect. Dis.
19:1029-1033[Medline].
|
| 12.
|
Curtis, A. S. G.
1973.
Cell adhesion.
Prog. Biophys. Mol. Biol.
27:317-386.
|
| 13.
|
Dealler, S. F.
1991.
Antibiotics induce rapid bacterial zeta potential changes.
J. Antimicrob. Chemother.
3:470-473.
|
| 14.
| Dismukes, W. E. 1993. Management of
cryptococcosis. Clin. Infect. Dis. 17(Suppl.
2):507-512.
|
| 15.
|
Drgonova, J.,
T. Drgon,
K. Tanaka,
R. Kollar,
G.-C. Chen,
R. A. Ford,
C. S. M. Chan,
Y. Takai, and E. Cabib.
1996.
Rho 1p, a yeast protein at the interface between cell polarization and morphogenesis.
Science
272:277-279[Abstract].
|
| 16.
|
Dromer, F., and J. Charreire.
1991.
Improved amphotericin B activity by a monoclonal anti-Cryptococcus neoformans antibody: study during murine cryptococcosis and mechanisms of action.
J. Infect. Dis.
163:1114-1120[Medline].
|
| 17.
|
Dromer, F.,
S. Mathoulin,
B. Dupont,
L. Letenneur, and O. Ronin.
1996.
Individual and environmental factors associated with infection due to Cryptococcus neoformans serotype D. French Cryptococcosis Study Group.
Clin. Infect. Dis.
23:91-96[Medline].
|
| 18.
|
Dugoni, B. M.,
B. J. Guglielmo, and H. Hollander.
1989.
Amphotericin B concentrations in cerebral spinal fluid in patients with AIDS and cryptococcal meningitis.
Clin. Pharmacol.
8:220-221[Medline].
|
| 19.
|
Dykstra, M. A.,
L. Friedman, and J. W. Murphy.
1977.
Capsule size of Cryptococcus neoformans: control and relationship to virulence.
Infect. Immun.
16:129-135[Abstract/Free Full Text].
|
| 20.
|
Franzot, S. P., and J. S. Hamdan.
1994.
Effect of amphotericin B on the lipids of five different strains of Cryptococcus neoformans.
Mycopathologia
128:85-89[Medline].
|
| 21.
|
Franzot, S. P.,
J. Mukherjee,
R. Cherniak,
L. C. Chen,
J. S. Hamdan, and A. Casadevall.
1998.
Microevolution of a standard strain of Cryptococcus neoformans resulting in differences in virulence and other phenotypes.
Infect. Immun.
66:89-97[Abstract/Free Full Text].
|
| 22.
|
Fromtling, R. A.,
H. J. Shadomy, and E. S. Jacobson.
1982.
Decreased virulence in stable, acapsular mutants of Cryptococcus neoformans.
Mycopathologia
79:23-29[Medline].
|
| 23.
|
Ghannoum, M. A.,
B. J. Spellberg,
A. S. Ibrahim,
J. A. Ritchie,
B. Currie,
E. D. Spitzer,
J. E. J. Edwards, and A. Casadevall.
1994.
Sterol composition of Cryptococcus neoformans in the presence and absence of fluconazole.
Antimicrob. Agents Chemother.
38:2029-2033[Abstract/Free Full Text].
|
| 24.
|
Goetz, P. J., and J. G. Penniman, Jr.
1976.
A new technique for microelectrophoretic measurements.
Am. Lab.
1976:212-230.
|
| 25.
|
Ikada, Y., and Y. Tabata.
1986.
Phagocytosis of bioactive microspheres.
J. Bioactive Compatible Polymers
1:32-46.
|
| 26.
|
Ikeda, R.,
T. Shinoda,
K. Kagaya, and Y. Fukazawa.
1984.
Role of serum factors in the phagocytosis of weakly or heavily encapsulated Cryptococcus neoformans strains by guinea pig peripheral blood leukocytes.
Microbiol. Immunol.
28:51-61[Medline].
|
| 27.
|
Illum, L.,
L. O. Jacobson,
R. H. Muller,
E. Mak, and S. S. Davis.
1987.
Surface characteristics and the interaction of colloidal particles with mouse peritoneal macrophages.
Biomaterials
8:113-117[Medline].
|
| 28.
|
Jacobson, E. S., and S. B. Tinnell.
1993.
Antioxidant function of fungal melanin.
J. Bacteriol.
175:7102-7104[Abstract/Free Full Text].
|
| 29.
|
Kawaguchi, H.,
N. Koiwai,
Y. Ohtsuka,
N. Miyamoto, and S. Sasakawa.
1986.
Phagocytosis of laxex particles by leukocytes. I. Dependence of phagocytosis on the size and surface potentials of particles.
Biomaterials
7:61-66[Medline].
|
| 30.
|
Kozel, T. R.,
B. C. deJong,
M. M. Grinsell,
R. S. MacGill, and K. K. Wall.
1998.
Characterization of anticapsular monoclonal antibodies that regulate activation of the complement system by the Cryptococcus neoformans capsule.
Infect. Immun.
66:1538-1546[Abstract/Free Full Text].
|
| 31.
|
Kozel, T. R., and E. C. Gotschlich.
1982.
The capsule of Cryptococcus neoformans passively inhibits phagocytosis of the yeast by macrophages.
J. Immunol.
129:1675-1680[Abstract].
|
| 32.
|
Kozel, T. R., and C. A. Hermerath.
1984.
Binding of cryptococcal polysaccharide to Cryptococcus neoformans.
Infect. Immun.
43:879-886[Abstract/Free Full Text].
|
| 33.
|
Kozel, T. R.,
E. Reiss, and R. Cherniak.
1980.
Concomitant but not causal association between surface charge and inhibition of phagocytosis by cryptococcal polysaccharide.
Infect. Immun.
29:295-300[Abstract/Free Full Text].
|
| 34.
|
Kwon-Chung, K. J., and J. C. Rhodes.
1986.
Encapsulation and melanin formation as indicators of virulence in Cryptococcus neoformans.
Infect. Immun.
51:218-223[Abstract/Free Full Text].
|
| 35.
|
Louria, D. B.
1958.
Some aspects of the absorption, distribution, and excretion of amphotericin B in man.
Antibiot. Med. Clin. Ther.
5:295-301.
|
| 36.
|
Mitchell, T. G., and J. R. Perfect.
1995.
Cryptococcus in the era of AIDS 100 years after the discovery of Cryptococcus neoformans.
Clin. Microbiol. Rev.
8:515-548[Abstract].
|
| 37.
|
Miyake, Y.,
T. Tsunoda,
S. Minagi,
Y. Akagawa,
H. Tsuru, and H. Suginaka.
1990.
Antifungal drugs affect adherence of Candida albicans to acrylic surfaces by changing the zeta-potential of fungal cells.
FEMS Microbiol. Lett.
69:211-214.
|
| 38.
|
Mozaffarian, N.,
J. W. Berman, and A. Casadevall.
1997.
Enhancement of nitric oxide synthesis by macrophages represents an additional mechanism of action for amphotericin B.
Antimicrob. Agents Chemother.
41:1825-1829[Abstract].
|
| 39.
|
Mozaffarian, N.,
J. W. Berman, and A. Casadevall.
1995.
Immune complexes increase nitric oxide production by interferon-gamma-stimulated murine macrophage-like J774.16 cells.
J. Leukoc. Biol.
57:657-662[Abstract].
|
| 40.
|
Mukherjee, J.,
M. Feldmesser,
M. D. Scharff, and A. Casadevall.
1995.
Monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan enhance fluconazole efficacy.
Antimicrob. Agents Chemother.
39:1398-1405[Abstract].
|
| 41.
|
Mukherjee, J.,
L. S. Zuckier,
M. D. Scharff, and A. Casadevall.
1994.
Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B.
Antimicrob. Agents Chemother.
38:580-587[Abstract/Free Full Text].
|
| 42.
|
Muratsugu, M.,
Y. Miyake,
N. Ishida,
A. Hyodo, and K. Terayama.
1995.
Decrease in surface charge density of Klebsiella pneumoniae treated with cefodizime and enhancement of phagocytic function of polymorphonuclear lymphocytes stimulated by the drug-treated bacteria.
Biol. Pharm. Bull.
18:1259-1263[Medline].
|
| 43.
|
Nagura, H.,
J. Asai,
Y. Katsumata, and K. Kojima.
1973.
Role of electric surface charge of cell membrane in phagocytosis.
Acta Pathol. Jpn.
23:279-290[Medline].
|
| 44.
|
Nassar, F.,
E. Brummer, and D. A. Stevens.
1995.
Different components in human serum inhibit multiplication of Cryptococcus neoformans and enhance fluconazole activity.
Antimicrob. Agents Chemother.
39:2490-2493[Abstract]. (Erratum, 40:1330, 1996.)
|
| 45.
|
National Committee for Clinical Laboratory Standards.
1992.
Reference method for broth dilution antifungal susceptibility testing for yeasts. Proposed standard M27-P.
National Committee for Clinical Laboratory Standards, Wayne, Pa.
|
| 46.
|
Nguyen, M. H.,
C. J. Clancy,
V. L. Yu,
V. C. Yu,
A. J. Morris,
D. R. Snydman,
D. A. Sutton, and M. G. Rinaldi.
1998.
Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia.
J. Infect. Dis.
177:425-430[Medline].
|
| 47.
|
Nosanchuk, J., and A. Casadevall.
1997.
Cellular charge of Cryptococcus neoformans: contributions from the capsular polysaccharide, melanin, and monoclonal antibody binding.
Infect. Immun.
65:1836-1841[Abstract].
|
| 48.
| Ohtomo, T., Y. Ohshima, Y. Usui, Y. Ichiman, N. Yanagisawa, E. Yokota, and J. Shimada. 1995. Effect of
sub-inhibitory concentrations of clarithromycin and erythromycin on the
production of Staphylococcus aureus capsules. J. Chemother.
7(Suppl. 4):9-11.
|
| 49.
|
Ramadan, M. A.,
A. F. Tawfik,
A. M. Shibl, and C. G. Gemmell.
1995.
Postantibiotic effect of azithromycin and erythromycin on streptococcal susceptibility to phagocytosis.
J. Med. Microbiol.
42:362-366[Abstract/Free Full Text].
|
| 50.
|
Richmond, D. V., and D. J. Fisher.
1973.
The electrophoretic mobility of microorganisms.
Adv. Microb. Physiol.
9:1-29[Medline].
|
| 51.
|
Saag, M. S., and W. E. Dismukes.
1988.
Azole antifungal agents: emphasis on new triazoles.
Antimicrob. Agents Chemother.
32:1-8[Abstract/Free Full Text].
|
| 52.
|
Sengar, A. S.,
N. A. Markley,
N. J. Marini, and D. Young.
1997.
Mkh1, a MEK kinase required for cell wall integrity and proper response to osmotic and temperature stress in Schizosaccharomyces pombe.
Mol. Cell. Biol.
17:3508-3519[Abstract].
|
| 53.
|
Small, J. M., and T. G. Mitchell.
1989.
Strain variation in antiphagocytic activity of capsular polysaccharides from Cryptococcus neoformans serotype A.
Infect. Immun.
57:3751-3756[Abstract/Free Full Text].
|
| 54.
|
Spitzer, E. D.,
S. G. Spitzer,
L. F. Freundlich, and A. Casadevall.
1993.
Persistence of the initial infection in recurrent cryptococcal meningitis.
Lancet
341:595-596[Medline].
|
| 55.
|
Tabata, Y., and Y. Ikada.
1988.
Effect of size and surface charge of polymer microspheres on their phagocytosis by macrophages.
Biomaterials
9:356-361[Medline].
|
| 56.
|
Tohyama, M.,
K. Kawakami, and A. Saito.
1996.
Anticryptococcal effects of amphotericin B is mediated through macrophage production of nitric oxide.
Antimicrob. Agents Chemother.
40:1919-1923[Abstract].
|
| 57.
|
Wilson, E.,
L. Thorson, and D. P. Speert.
1991.
Enhancement of macrophage superoxide anion production by amphotericin B.
Antimicrob. Agents Chemother.
35:796-800[Abstract/Free Full Text].
|
| 58.
|
Wolf, J. E., and S. E. Massof.
1990.
In vivo activation of macrophage oxidative burst activity by cytokines and amphotericin B.
Infect. Immun.
58:1296-1300[Abstract/Free Full Text].
|
| 59.
|
Yamaguchi, H.,
S. Abe, and Y. Tokuda.
1993.
Immunomodulating activity of antifungal drugs.
Ann. N. Y. Acad. Sci.
685:447-457[Medline].
|
| 60.
|
Yasuoka, A.,
S. Kohno,
H. Yamada,
M. Kaku, and H. Koga.
1994.
Influence of molecular sizes of Cryptococcus neoformans capsular polysaccharide on phagocytosis.
Microbiol. Immunol.
38:851-856[Medline].
|
| 61.
|
Zuger, A.,
E. Louie,
R. S. Holzman,
M. S. Simberkoff, and J. J. Rahal.
1986.
Cryptococcal disease in patients with the acquired immunodeficiency syndrome: diagnostic features and outcome of treatment.
Ann. Intern. Med.
104:234-240.
|
Antimicrobial Agents and Chemotherapy, February 1999, p. 233-239, Vol. 43, No. 2
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Martinez, L. R., Ntiamoah, P., Gacser, A., Casadevall, A., Nosanchuk, J. D.
(2007). Voriconazole Inhibits Melanization in Cryptococcus neoformans. Antimicrob. Agents Chemother.
51: 4396-4400
[Abstract]
[Full Text]
-
Benincasa, M., Scocchi, M., Pacor, S., Tossi, A., Nobili, D., Basaglia, G., Busetti, M., Gennaro, R.
(2006). Fungicidal activity of five cathelicidin peptides against clinically isolated yeasts. J Antimicrob Chemother
58: 950-959
[Abstract]
[Full Text]
-
Lepak, A., Nett, J., Lincoln, L., Marchillo, K., Andes, D.
(2006). Time Course of Microbiologic Outcome and Gene Expression in Candida albicans during and following In Vitro and In Vivo Exposure to Fluconazole.. Antimicrob. Agents Chemother.
50: 1311-1319
[Abstract]
[Full Text]
-
Martinez, L. R., Casadevall, A.
(2006). Susceptibility of Cryptococcus neoformans Biofilms to Antifungal Agents In Vitro. Antimicrob. Agents Chemother.
50: 1021-1033
[Abstract]
[Full Text]
-
Zaragoza, O., Mihu, C., Casadevall, A., Nosanchuk, J. D.
(2005). Effect of Amphotericin B on Capsule and Cell Size in Cryptococcus neoformans during Murine Infection. Antimicrob. Agents Chemother.
49: 4358-4361
[Abstract]
[Full Text]
-
Copping, V. M. S., Barelle, C. J., Hube, B., Gow, N. A. R., Brown, A. J. P., Odds, F. C.
(2005). Exposure of Candida albicans to antifungal agents affects expression of SAP2 and SAP9 secreted proteinase genes. J Antimicrob Chemother
55: 645-654
[Abstract]
[Full Text]
-
Yeaman, M. R., Cheng, D., Desai, B., Kupferwasser, L. I., Xiong, Y.-Q., Gank, K. D., Edwards, J. E. Jr., Bayer, A. S.
(2004). Susceptibility to Thrombin-Induced Platelet Microbicidal Protein Is Associated with Increased Fluconazole Efficacy against Experimental Endocarditis Due to Candida albicans. Antimicrob. Agents Chemother.
48: 3051-3056
[Abstract]
[Full Text]
-
van Duin, D., Cleare, W., Zaragoza, O., Casadevall, A., Nosanchuk, J. D.
(2004). Effects of Voriconazole on Cryptococcus neoformans. Antimicrob. Agents Chemother.
48: 2014-2020
[Abstract]
[Full Text]
-
Nakouzi, A., Valadon, P., Nosanchuk, J., Green, N., Casadevall, A.
(2001). Molecular Basis for Immunoglobulin M Specificity to Epitopes in Cryptococcus neoformans Polysaccharide That Elicit Protective and Nonprotective Antibodies. Infect. Immun.
69: 3398-3409
[Abstract]
[Full Text]
-
Andes, D., Stamsted, T., Conklin, R.
(2001). Pharmacodynamics of Amphotericin B in a Neutropenic-Mouse Disseminated-Candidiasis Model. Antimicrob. Agents Chemother.
45: 922-926
[Abstract]
[Full Text]
-
Diniz, C. G., Cara, D. C., Nicoli, J. R., Farias, L. D. M., De Carvalho, M. A. R.
(2000). Effect of Metronidazole on the Pathogenicity of Resistant Bacteroides Strains in Gnotobiotic Mice. Antimicrob. Agents Chemother.
44: 2419-2423
[Abstract]
[Full Text]
-
Pitzurra, L., Fringuelli, R., Perito, S., Schiaffella, F., Barluzzi, R., Bistoni, F., Vecchiarelli, A.
(1999). A New Azole Derivative of 1,4-Benzothiazine Increases the Antifungal Mechanisms of Natural Effector Cells. Antimicrob. Agents Chemother.
43: 2170-2175
[Abstract]
[Full Text]